Novel agents in relapsed/refractory diffuse large B-cell lymphoma

被引：8

作者：

Varma, Gaurav ^{[1
]}

Goldstein, Jordan ^{[2
]}

Advani, Ranjana H. ^{[2
,3
]}

机构：

[1] NYU, Dept Med, Div Hematol & Med Oncol, Grossman Sch Med, New York, NY USA

[2] Stanford Univ, Dept Med, Div Oncol, Stanford, CA USA

[3] Stanford Canc Inst, Lymphoma, 875 BlakeWilbur Dr, Stanford, CA 94305 USA

来源：

HEMATOLOGICAL ONCOLOGY | 2023年 / 41卷

关键词：

DLBCL; novel agents; relapsed; refractory; NON-HODGKIN-LYMPHOMA; POLATUZUMAB VEDOTIN; SINGLE-ARM; OPEN-LABEL; BRENTUXIMAB VEDOTIN; CD30; EXPRESSION; LENALIDOMIDE; RITUXIMAB; MULTICENTER; SAFETY;

D O I：

10.1002/hon.3143

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), ineligible for or relapsing after autologous stem-cell transplant or chimeric antigen-receptor T-cell therapies have poor outcomes. Several novel agents, polatuzumab vedotin, tafasitamab, loncastuximab tesirine, and selinexor, have been approved and offer new opportunities for this difficult to treat population. Studies are evaluating combination of these agents with chemotherapy and other emerging therapies. Additionally, advances in our understanding of DLBCL biology, genetics, and immune microenvironment have allowed for the identification of new therapeutic targets like Ikaros and Aiolos, IRAK4, MALT1, and CD47 with several agents in ongoing clinical trials. In this chapter we review updated data supporting the use of the approved agents and discuss other emerging novel therapies for patients with R/R DLBCL.

引用

页码：92 / 106

页数：15

共 106 条

[1] PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma [J].

Abubaker, J. ;

Bavi, P. P. ;

Al-Harbi, S. ;

Siraj, A. K. ;

Al-Dayel, F. ;

Uddin, S. ;

Al-Kuraya, K. .

LEUKEMIA, 2007, 21 (11) :2368-2370

[2] CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma [J].

Advani, Ranjana ;

Flinn, Ian ;

Popplewell, Leslie ;

Forero, Andres ;

Bartlett, Nancy L. ;

Ghosh, Nilanjan ;

Kline, Justin ;

Roschewski, Mark ;

LaCasce, Ann ;

Collins, Graham P. ;

Thu Tran ;

Lynn, Judith ;

Chen, James Y. ;

Volkmer, Jens-Peter ;

Agoram, Balaji ;

Huang, Jie ;

Majeti, Ravindra ;

Weissman, Irving L. ;

Takimoto, Chris H. ;

Chao, Mark P. ;

Smith, Sonali M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (18) :1711-1721

[3] Exploiting the mammalian target of rapamycin pathway in hematologic malignancies [J].

Altman, Jessica K. ;

Platanias, Leonidas C. .

CURRENT OPINION IN HEMATOLOGY, 2008, 15 (02) :88-94

[4]

[Anonymous], NCCN B CELL LYMPHOMA

[5] Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies [J].

Ansell, Stephen M. ;

Maris, Michael B. ;

Lesokhin, Alexander M. ;

Chen, Robert W. ;

Flinn, Ian W. ;

Sawas, Ahmed ;

Minden, Mark D. ;

Villa, Diego ;

Percival, Mary-Elizabeth M. ;

Advani, Anjali S. ;

Foran, James M. ;

Horwitz, Steven M. ;

Mei, Matthew G. ;

Zain, Jasmine ;

Savage, Kerry J. ;

Querfeld, Christiane ;

Akilov, Oleg E. ;

Johnson, Lisa D. S. ;

Catalano, Tina ;

Petrova, Penka S. ;

Uger, Robert A. ;

Sievers, Eric L. ;

Milea, Anca ;

Roberge, Kathleen ;

Shou, Yaping ;

O'Connor, Owen A. .

CLINICAL CANCER RESEARCH, 2021, 27 (08) :2190-2199

[6]

Bartlett NL, 2022, J CLIN ONCOL, V40

[7] Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry [J].

Bartlett, Nancy L. ;

Smith, Mitchell R. ;

Siddiqi, Tanya ;

Advani, Ranjana H. ;

O'Connor, Owen A. ;

Sharman, Jeff P. ;

Feldman, Tatyana ;

Savage, Kerry J. ;

Shustov, Andrei R. ;

Diefenbach, Catherine S. ;

Oki, Yasuhiro ;

Palanca-Wessels, Maria Corinna ;

Uttarwar, Mayur ;

Li, Martha ;

Yang, Jing ;

Jacobsen, Eric D. .

LEUKEMIA & LYMPHOMA, 2017, 58 (07) :1607-1616

[8] Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4 [J].

Bjorklund, C. C. ;

Lu, L. ;

Kang, J. ;

Hagner, P. R. ;

Havens, C. G. ;

Amatangelo, M. ;

Wang, M. ;

Ren, Y. ;

Couto, S. ;

Breider, M. ;

Ning, Y. ;

Gandhi, A. K. ;

Daniel, T. O. ;

Chopra, R. ;

Klippel, A. ;

Thakurta, A. G. .

BLOOD CANCER JOURNAL, 2015, 5 :e354-e354

[9] PK and PD Assessment of BET Inhibitor Pelabresib (CPI-0610) in Patients with Relapsed or Refractory Lymphoma: Findings from a Phase 1 Study [J].

Blum, Kristie A. ;

Supko, Jeffrey G. ;

Maris, Michael ;

Flinn, Ian W. ;

Goy, Andre H. ;

Younes, Anas ;

Bobba, Suresh ;

Senderowicz, Adrian ;

Efuni, Sergey ;

Rippley, Ronda ;

Abramson, Jeremy S. .

BLOOD, 2021, 138

[10] Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial [J].

Caimi, Paolo F. ;

Ai, Weiyun ;

Alderuccio, Juan Pablo ;

Ardeshna, Kirit M. ;

Hamadani, Mehdi ;

Hess, Brian ;

Kahl, Brad S. ;

Radford, John ;

Solh, Melhem ;

Stathis, Anastasios ;

Zinzani, Pier Luigi ;

Havenith, Karin ;

Feingold, Jay ;

He, Shui ;

Qin, Yajuan ;

Ungar, David ;

Zhang, Xiaoyan ;

Carlo-Stella, Carmelo .

LANCET ONCOLOGY, 2021, 22 (06) :790-800

← 1 2 3 4 5 6 7 8 9 10 →